Roche’s Hemlibra Battles Fierce Competition Amid Rating Hold
Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
- Latest
- Trending
Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...
Bitcoin dominates with 60% of crypto transaction volume. TRON and Ethereum follow. 70% of drug precursor sales linked to 11 ...
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Senate subpoenas Novo's Langa over drug pricing; Jorgensen to testify in September as Novo blames U.S. health system for high ...
Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Swiss chemist Albert Hofmann first synthesized LSD in the 1930s. While research eventually halted, the drug is now being decriminalized ...
The US Court of Appeals ruled that forcing someone to use their biometrics to unlock a phone is not testimonial. ...
The Open Medical-LLM leaderboard offers valuable insights into AI-related medical devices, although none of the approved devices use generative AI.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.